RESULTS: This study expressed the recombinant proteins Hpf, HPF-NE and HPF-T34E via an E. coli expression system. The results showed that the recombinant proteins Hpf, Hpf-NE and Hpf-T34E could be effectively assembled into nanoparticles. Subsequently, we evaluated the immunogenicity of the Hpf, Hpf-NE and Hpf-T34E proteins in mice, as well as the immunogenicity and protectiveness of the Hpf-T34E protein in guinea pigs. The results of the mouse experiment showed that the immune efficacy in the Hpf-T34E group was greater than the Hpf-NE group. The results from guinea pigs immunized with Hpf-T34E showed that the immune efficacy was largely consistent with the immunogenicity of the FMD inactivated vaccine (IV) and could confer partial protection against FMDV challenge in guinea pigs.
CONCLUSIONS: The Hpf-T34E nanoparticles stand out as a superior choice for a subunit vaccine candidate against FMD, offering effective protection in FMDV-infected model animals. FNP-based vaccines exhibit excellent safety and immunogenicity, thus representing a promising strategy for the continued development of highly efficient and safe FMD vaccines.
结果:本研究表达了重组蛋白Hpf,HPF-NE和HPF-T34E通过大肠杆菌表达系统。结果表明,重组蛋白Hpf,Hpf-NE和Hpf-T34E可以有效地组装成纳米颗粒。随后,我们评估了Hpf的免疫原性,小鼠Hpf-NE和Hpf-T34E蛋白,以及Hpf-T34E蛋白在豚鼠中的免疫原性和保护性。小鼠试验成果显示Hpf-T34E组的免疫效力年夜于Hpf-NE组。用Hpf-T34E免疫的豚鼠的结果表明,免疫效力与FMD灭活疫苗(IV)的免疫原性基本一致,并且可以在豚鼠中提供针对FMDV攻击的部分保护。
结论:Hpf-T34E纳米颗粒作为抗口蹄疫亚单位疫苗候选物较好的选择,在FMDV感染的模型动物中提供有效的保护。基于FNP的疫苗表现出优异的安全性和免疫原性,因此代表了继续开发高效和安全的FMD疫苗的有希望的策略。